Search results for "Side effect"

showing 10 items of 189 documents

Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients…

2017

Introduction: Stimulation-evoked focal to bilateral tonic-clonic seizure (FBTCS) can be a stressful and possibly harmful adverse event for patients during cortical stimulation (CS). We evaluated if drug load reduction of anti epileptic drugs (AEDs) during CS increases the risk of stimulation-evoked FBTCS. Material and methods: In this retrospective cohort study, we searched our local database for patients with drug resistant epilepsy who underwent invasive video-EEG monitoring and CS in the University Hospital la Fe Valencia from January 2006 to November 2016. The AED drug load was calculated with the defined daily dose. We applied a uni- and multivariate logistic regression model to estima…

0301 basic medicineAdultMalemedicine.medical_specialtyDrug Resistant EpilepsyNeurologyAdolescentDrug-Related Side Effects and Adverse ReactionsStimulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineEpilepsy surgerySeizuresmedicineOdds RatioHumansEpilepsy surgeryAdverse effectRetrospective Studiesbusiness.industryRetrospective cohort studyElectroencephalographyOdds ratioMiddle Agedmedicine.diseaseElectric Stimulation030104 developmental biologyDefined daily doseLogistic ModelsTreatment OutcomeNeurologyElectrical stimulationWithdrawalAnesthesiaDefined daily doseAnticonvulsantsEpilepsy GeneralizedFemaleNeurology (clinical)Epilepsies PartialEpilepsy Tonic-ClonicSafetybusinessGeneralized tonic-clonic seizure030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodyspla…

2017

This is an observational-retrospective study comparing the real-world outcomes associated with posaconazole vs. itraconazole as prophylaxis treatments. Two hundred and ninety-three patient admissions attributable to 174 patients were included in the study. Patients were treated with itraconazole (n = 114 admissions; 39%) or posaconazole (n = 179; 61%). Antifungal prophylaxis failure (APF) due to treatment-related adverse events (in 34 out of 293 patient admissions; 11.6%) was more frequent in the posaconazole group (6.1% vs. 15.1%; P = 0.024). There were 9 patient admissions for episodes of APF due to probable/proven breakthrough fungal infection (primary endpoint): 6 and 3 in the itraconaz…

0301 basic medicineAdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsDrug-Related Side Effects and Adverse ReactionsItraconazole030106 microbiologyDermatologyNeutropenia03 medical and health sciencesInternal medicinemedicineClinical endpointHumansIn patientTreatment FailureAdverse effectAgedRetrospective StudiesInvasive Pulmonary Aspergillosisbusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesMyelodysplastic SyndromesFemalePre-Exposure ProphylaxisItraconazolebusinessInvasive Fungal Infectionsmedicine.drugMycoses
researchProduct

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.

2017

Abstract Context Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective Evaluate efficacy of add-on Se on medical treatment in GD. Design Double-blind, placebo-controlled, randomized supplementation trial. Setting Academic endocrine outpatient clinic. Patients Seventy untreated hyperthyroid patients with GD. Intervention Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. Main Outcome Measures Response rate (week 24), recurrence rate (week 36), and safety. Results A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) a…

0301 basic medicineAdultMalemedicine.medical_specialtySide effectEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)PlaceboBiochemistryHyperthyroidismlaw.inventionPlacebos03 medical and health sciencesSelenium0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicineMedicineOutpatient clinicHumansEuthyroidAdverse effectbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseGraves Disease030104 developmental biologyEndocrinologyTreatment OutcomeDietary SupplementsFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-con…

2021

Background: Allergic rhinitis induced by house dust mites (HDMs) is a highly prevalent but often underdiagnosed and undertreated/untreated chronic disease. It often has a negative impact on sleep, work, leisure activities, and health-related quality of life. Allergen immunotherapy is a proven, safe treatment for respiratory allergies. Objective: We sought to assess the efficacy and safety of a 300 index of reactivity (IR) sublingual tablet formulation of Dermatophagoides pteronyssinus:Dermatophagoides farinae 1:1 extract in adolescents (aged >_12) and adults with moderate to severe HDM-induced allergic rhinitis. Methods: In a phase III, international, double-blind, placebo controlled, rando…

0301 basic medicineAllergen immunotherapy; allergic rhinitis; allergy; house-dust mite; medication score; sublingual immunotherapy; symptom score; tablet; total combined scoreMaleAllergyInternational Cooperation*total combined scoreSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallaw*allergyClinical endpointImmunology and Allergy[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergologyhouse dust miteAllergen immunotherapybiologyPyroglyphidae*tablet*allergic rhinitis*sublingual immunotherapy3. Good healthhouse-dust mitetotal combined score*Allergen immunotherapyFemale[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology*medication scoreAdultAllergen immunotherapymedicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse ReactionsImmunologyPlacebosublingual immunotherapymedication score03 medical and health sciencesYoung AdultDouble-Blind MethodInternal medicinemedicineAnimalsHumansAntigens DermatophagoidesAsthmaHouse dust mitetabletSublingual Immunotherapyallergic rhinitisbusiness.industry[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapymedicine.diseasebiology.organism_classificationallergyPlacebo EffectRhinitis Allergic*symptom scoresymptom scoreClinical trial030104 developmental biology030228 respiratory system*house-dust miteQuality of LifebusinessThe Journal of allergy and clinical immunology
researchProduct

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to succ…

2019

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods:…

0301 basic medicineCancer ResearchReviewDiseasechemistry.chemical_compound0302 clinical medicineRibociclibMolecular Targeted TherapyAbemaciclibClinical Trials as TopicDisease ManagementMetastatic breast cancerEverolimuOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleAdvanced breast cancerReceptors ProgesteroneBreast Neoplasmmedicine.drugHumanmedicine.medical_specialtyNeutropeniaDrug-Related Side Effects and Adverse ReactionsAntineoplastic Agents HormonalProtein Kinase InhibitorBreast NeoplasmsPalbociclibPalbociclib03 medical and health sciencesBreast cancermedicineBiomarkers TumorHumansEverolimusIntensive care medicineAdverse effectProtein Kinase InhibitorsEverolimusbusiness.industrymedicine.diseaseClinical trialAbemaciclib030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessDrug-Related Side Effects and Adverse ReactionAbemaciclib; Advanced breast cancer; Everolimus; Neutropenia; Palbociclib; Ribociclib
researchProduct

Hydroxyurea‑induced superinfected ulcerations: Two case reports and review of the literature

2020

The chronic use of hydroxyurea (HU) in some oncologic and non-oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy. Likewise, oral ulcerations and stomatitis may occur at mucosal level. Hair damage can be expressed through alopecia and nail damage through melanonychia and oncycholysis. First case, a 63-year-old woman with severe psoriasis vulgaris and chronic granulocytic leukemia, with 5 years of HU therapy…

0301 basic medicineCancer Researchmedicine.medical_specialtyErythemaMucocutaneous zoneleg ulcersmedicine.disease_causehydroxyurea03 medical and health sciences0302 clinical medicineImmunology and Microbiology (miscellaneous)PsoriasismedicineStomatitiscutaneousbusiness.industrysuperinfectedArticlesGeneral Medicinemedicine.diseaseHyperpigmentationDermatologyside effects030104 developmental biologyMelanonychia030220 oncology & carcinogenesisCellulitisSuperinfectionmedicine.symptombusinessExperimental and Therapeutic Medicine
researchProduct

Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and…

2016

A 52-year-old male patient was treated with standard radiochemotherapy with temozolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, further tumor-specific treatment was unlikely to be successful, and the patient seeked help from an alternative practitioner, who administered a combination of dichloroacetate (DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite successful restoration of laboratory parameters upon symptomatic treatment, the patient died 10 days after the infusion. DCA bears a well-documented hepatotoxic risk, while ART can…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCase ReportToxicologychemotherapyGastroenterologylcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedizinische FakultätInternal medicineadverse effectmedicineddc:610Adverse effectCancerLiver injuryChemotherapyLeukopeniaTemozolomidebusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryClinical trial030104 developmental biologychemistryOncologyArtesunate030220 oncology & carcinogenesisadverse side effectsErythropoiesismedicine.symptombusinessmedicine.drugcomplementary and alternative medicine
researchProduct

Bevacizumab diminishes inflammation in an acute endotoxin-induced uveitis model

2017

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2018.00649/full Introduction: Uveitis is an eye disease characterized by inflammation of the uvea and an early and exhaustive diagnosis is essential for its treatment. The aim of our study is to assess the potential toxicity and anti-inflammatory efficacy of Bevacizumab in an experimental uveitis model by subcutaneously injecting lipopolysaccharide into Lewis rats and to clarify its mechanism. Material and Methods: Blood–aqueous barrier integrity was assessed 24 h after endotoxin-induced uveitis (EIU) by analyzing two parameters: cell count and protein…

0301 basic medicineChemokineLipopolysaccharidegenetic structuresmedicine.medical_treatmentÚvea - Efectos de los medicamentos.chemokinesPharmacologymedicine.disease_causeendotoxin-induced uveitischemistry.chemical_compound0302 clinical medicineMedicineoxidative stressPharmacology (medical)Bevacizumab - Efectos fisiológicos.Bevacizumab - Efectos secundarios.Uvea - Effect of drugs on.Original ResearchEstrés oxidativo.biologyOxidative stress.medicine.anatomical_structureCytokineToxicityOjos - Enfermedades - Tratamiento.medicine.symptomUveitisPharmacology.InflammationFarmacología.bevacizumabBevacizumab - Physiological effect.Bevacizumab - Side effects.03 medical and health sciencesUveitis - Treatment.Eyes - Diseases - Treatment.Pharmacologybusiness.industrylcsh:RM1-950Uveítis - Tratamiento.Uveamedicine.diseaseeye diseasescytokines030104 developmental biologylcsh:Therapeutics. Pharmacologychemistryinflammation030221 ophthalmology & optometrybiology.proteinsense organsbusinessOxidative stress
researchProduct

Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis

2016

Only a few in vitro assays have been proposed to evaluate the steatotic potential of new drugs. The present study examines the utility of HepaRG cells as a cell-based assay system for screening drug-induced liver steatosis. A high-content screening assay was run to evaluate multiple toxicity-related cell parameters in HepaRG cells exposed to 28 compounds, including drugs reported to cause steatosis through different mechanisms and non-steatotic compounds. Lipid content was the most sensitive parameter for all the steatotic drugs, whereas no effects on lipid levels were produced by non-steatotic compounds. Apart from fat accumulation, increased ROS production and altered mitochondrial membra…

0301 basic medicineDrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectCellDrug Evaluation PreclinicalBiologyPharmacologyToxicology03 medical and health sciencesCell Line TumormedicineHumansTranscription factormedia_commonPharmacologyMembrane potentialFatty liverIn vitro toxicologyLipid metabolismLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologymedicine.anatomical_structureSteatosisToxicology and Applied Pharmacology
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct